Over 23 million people worldwide live with heart failure. This number increases by more than 500.000 each year. Many patients progress to advanced stages of the disease where symptoms like shortness of breath at rest or fatigue occur. Frequent hospitalizations are necessary. The number of patients by far exceeds the currently available treatment options.
AdjuCor develops new extravascular devices for individualized biventricular augmentation of the failing heart. The company’s mission is to enable such patients to regain quality of life, by a reduction of associated symptoms and an improvement of physical constitution.
We are a group with multidisciplinary expertise.
AdjuCor continuously receives expert advice for the improvement of their heart failure devices.
AdjuCor uses imaging data to respect the specific individual anatomy of each patient’s heart. It results in enhanced functionality and efficiency of the cardiac assist devices. The implants are positioned outside the blood stream with no need for device dependent anticoagulation. This results in the reduction of risk for stroke and bleeding, both being the predominant causes for re-hospitalization.
AdjuCor benefits from various cooperative R&D projects with partners from academia and industry.
Within the cooperative projects with their scientific partners, AdjuCor is funded and supported by the German Ministry of Education and Research, the German Ministry of Economic Affairs and Energy, the State of Bavaria and the European Union.
Unsolicited applications are welcome.
AdjuCor is a high-tech medical technology company. We are continuously looking for specialists from medicine, biotechnology, mechanical and electronic engineering that are interested in the research and development of medical device technology.
If you have any questions or need information, please call or email us:
Managing Director: Professor Dr. med. Stephen Wildhirt
UId: DE 271301817